Abstract
We studied the interaction of the antitumor agent abiraterone and its pharmacologically active metabolite D4A, which is promising for use as an agent for the treatment of prostate cancer, with cytochrome P450 2C9 (CYP2C9). Using the absorption spectroscopy, it has been shown that both compounds under study cause spectral changes of CYP2C9, indicating the interaction of the nitrogen atom of the pyridine ring of the ligand with the heme iron ion of the active site of the enzyme. However, the ligand–enzyme interaction, which is mediated by water bound to the heme iron ion, is possible. Based on the spectral changes, the values of dissociation constants (KS) of the complexes of abiraterone and D4A with CYP2C9 were determined, which amounted to 1.73 ± 0.14 µM and 3.95 ± 0.16 µM, respectively. Both compounds inhibited the O-demethylase activity of CYP2C9 toward the substrate of this enzyme, naproxen. At a naproxen concentration of 100 µM, the concentrations of abiraterone, D4A, and sulfaphenazole, which inhibit CYP2C9 activity by 50% (IC50), were determined as 13.9 µM, 40 µM, and 41 µM, respectively. The data obtained can be used to predict drug-drug interactions at the CYP2C9 level when using abiraterone or D4A as an antitumor agent for the treatment of prostate cancer in complex pharmacotherapy.
Similar content being viewed by others
REFERENCES
Li, Z., Bishop, A.C., Alyamani, M., Garcia, J.A., Dreicer, R., Bunch, D., Liu, J., Upadhyay, S.K., Auchus, R.J., and Sharifi, N., Nature, 2015, vol. 523, pp. 347–351. https://doi.org/10.1038/nature14406
Yoshimoto, F.K. and Auchus, R.J., J. Steroid Biochem. Mol. Biol., 2015, vol. 151, pp. 52–65. https://doi.org/10.1016/j.jsbmb.2014.11.026
Attard, G., Reid, A.H., Auchus, R.J., Hughes, B.A., Cassidy, A.M., Thompson, E., Oommen, N.B., Folkerd, E., Dowsett, M., Arlt, W., and de Bono, J.S., J. Clin. Endocrinol. Metab., 2012, vol. 97, no. 2, pp. 507–516. https://doi.org/10.1210/jc.2011-2189
Li, Z., Alyamani, M., Li, J., Rogacki, K., Abazeed, M., Upadhyay, S.K., Balk, S.P., Taplin, M.E., Auchus, R.J., and Sharifi, N., Nature, 2016, vol. 533, no. 7604, pp. 547–551. https://doi.org/10.1038/nature17954
Salvador, J.A., Pinto, R.M., and Silvestre, S.M., J. Steroid Biochem. Mol. Biol., 2013, vol. 137, pp. 199–222. https://doi.org/10.1016/j.jsbmb.2013.04.006
Bonnet, C., Boudou-Rouquette, P., Azoulay-Rutman, E., Huillard, O., Golmard, J.-L., Carton, E., Noé, G., Vidal, M., Orvoen, G., Wakilian, A.C., Villeminey, C., Blanchet, B., Alexandre, J., Goldwasser, F., and Thomas-Schoemann, A., Cancer Chemother. Pharmacol., 2017, vol. 79, pp. 1051–1055. https://doi.org/10.1007/s00280-017-3291-z
del Re, M., Fogli, S., Derosa, L., Massari, F., de Souza, P., Crucitta, S., Bracarda, S., Santini, D., and Danesi, R., Cancer Treat. Rev., 2017, vol. 55, pp. 71–82. https://doi.org/10.1016/j.ctrv.2017.03.001
Masamrekh, R.A., Kuzikov, A.V., Haurychenka, Y.I., Shcherbakov, K.A., Veselovsky, A.V., Filimo-nov, D.A., Dmitriev, A.V., Zavialova, M.G., Gilep, A.A., Shkel, T.V., Strushkevich, N.V., Usa-nov, S.A., Archakov, A.I., and Shumyantseva, V.V., Fundam. Clin. Pharmacol., 2020, vol. 34, no. 1, pp. 120–130. https://doi.org/10.1111/fcp.12497
Friedlander, T.W. and Ryan, C.J., Drug Management of Prostate Cancer, Figg, W., Chau, C., and Small, E., Eds., New York: Springer, 2010, pp. 91–100. https://doi.org/10.1007/978-1-60327-829-4_8
Malikova, J., Brixius-Anderko, S., Udhane, S.S., Parween, S., Dick, B., Bernhardt, R., and Pandey, A.V., J. Steroid Biochem. Mol. Biol., 2017, vol. 174, pp. 192–200. https://doi.org/10.1016/j.jsbmb.2017.09.007
Masamrekh, R., Filippova, T., Haurychenka, Y., Shcherbakov, K., Veselovsky, A., Strushkevich, N., Shkel, T., Gilep, A., Usanov, S., Shumyantseva, V., and Kuzikov, A., Steroids, 2020, vol. 154, p. 108528. https://doi.org/10.1016/j.steroids.2019.108528
Garrido, M., Peng, H.M., Yoshimoto, F.K., Upadhyay, S.K., Bratoeff, E., and Auchus, R.J., J. Steroid Biochem. Mol. Biol., 2014, vol. 143, pp. 1–10. https://doi.org/10.1016/j.jsbmb.2014.01.013
Masamrekh, R.A., Filippova, T.A., Haurychenka, Y.I., Sherbakov, K.A., Veselovsky, A.V., Shumyantseva, V.V., and Kuzikov, A.V., Steroids, 2020, vol. 162, p. 108693. https://doi.org/10.1016/j.steroids.2020.108693
Louet, M., Labbé, C.M., Fagnen, C., Aono, C.M., Homem-de-Mello, P., Villoutreix, B.O., and Miteva, M.A., PLoS One, 2018, vol. 13, no. 5, p. e0197249. https://doi.org/10.1371/journal.pone.0197249
Daly, A.K., Rettie, A.E., Fowler, D.M., and Miners, J.O., J. Pers. Med., 2017, vol. 8, no. 1, p. 1. https://doi.org/10.3390/jpm8010001
Hoy, S.M., Drugs, 2013, vol. 73, no. 18, pp. 2077–2091. https://doi.org/10.1007/s40265-013-0150-z
Haidukevich, I.V., Sushko, T.A., Tumilovich, A.M., Grabovec, I.P., Usanov, S.A., and Gilep, A.A., Toxicol. In Vitro, 2018, vol. 50, pp. 249–256. https://doi.org/10.1016/j.tiv.2018.04.002
Omura, T. and Sato, R., J. Biol. Chem., 1964, vol. 239, pp. 2379–2385.
Swain, N.A., Batchelor, D., Beaudoin, S., Bechle, B.M., Bradley, P.A., Brown, A.D., Brown, B., Butcher, K.J., Butt, R.P., Chapman, M.L., Denton, S., Ellis, D., Galan, S.R.G., Gaulier, S.M., Greener, B.S., de Groot, M.J., Glossop, M.S., Gurrell, I.K., Hannam, J., Johnson, M.S., Lin, Z., Markworth, C.J., Marron, B.E., Millan, D.S., Nakagawa, S., Pike, A., Printzenhoff, D., Rawson, D.J., Ransley, S.J., Reister, S.M., Sasaki, K., Storer, R.I., Stupple, P.A., and West, C.W., J. Med. Chem., 2017, vol. 60, no. 16, pp. 7029–7042. https://doi.org/10.1021/acs.jmedchem.7b00598
Trott, O. and Olson, A.J., J. Comput. Chem., 2010, vol. 31, no. 2, pp. 455–461. https://doi.org/10.1002/jcc.21334
Adasme, M.F., Linnemann, K.L., Bolz, S.N., Kaiser, F., Salentin, S., Haupt, V.J., and Schroe-der, M., Nucleic Acids Res., 2021, vol. 49, no. W1, pp. W530–W534. https://doi.org/10.1093/nar/gkab294
Kuzikov, A.V., Filippova, T.A., Masamrekh, R.A., and Shumyantseva, V.V., J. Electroanalytical Chemistry, 2022, vol. 904, p. 115937. https://doi.org/10.1016/j.jelechem.2021.115937
Shumyantseva, V.V., Bulko, T.V., Koroleva, P.I., Sh-ikh, E.V., Makhova, A.A., Kisel, M.S., Haiduke-vich, I.V., and Gilep, A.A., Processes, 2022, vol. 10, no. 2, p. 383. https://doi.org/10.3390/pr10020383
Nash, T., Biochem. J., 1953, vol. 55, no. 3, pp. 416–421. https://doi.org/10.1042/bj0550416
Luthra, A., Denisov, I.G., and Sligar, S.G., Arch. Biochem. Biophys., 2011, vol. 507, no. 1, pp. 26–35. https://doi.org/10.1016/j.abb.2010.12.008
Denisov, I.G., Frank, D.J., and Sligar, S.G., Pharmacol. Ther., 2009, vol. 124, no. 2, pp. 151–167. https://doi.org/10.1016/j.pharmthera.2009.05.011
Bourrié, M., Meunier, V., Berger, Y., and Fabre, G., J. Pharmacol. Exp. Ther., 1996, vol. 277, no. 1, pp. 321–332.
Miners, J.O., Coulter, S., Tukey, R.H., Verone-se, M.E., and Birkett, D.J., Biochem. Pharmacol., 1996, vol. 51, no. 8, pp. 1003–1008. https://doi.org/10.1016/0006-2952(96)85085-4
van Booven, D., Marsh, S., McLeod, H., Carrillo, M.W., Sangkuhl, K., Klein, T.E., and Altman, R.B., Pharmacogenet. Genomics, 2010, vol. 20, no. 4, pp. 277–281. https://doi.org/10.1097/FPC.0b013e3283349e84
Funding
The work was financially supported by the Russian Science Foundation (project no. 17-75-20250).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
The authors declare that they have no conflicts of interest.
This article does not contain any studies involving animals or human participants performed by any of the authors.
Additional information
Translated by G. Levit
Rights and permissions
About this article
Cite this article
Masamrekh, R.A., Kuzikov, A.V., Filippova, T.A. et al. Interaction of Abiraterone and Its Pharmacologically Active Metabolite D4A with Cytochrome P450 2C9 (CYP2C9). Biochem. Moscow Suppl. Ser. B 16, 328–339 (2022). https://doi.org/10.1134/S1990750822040059
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S1990750822040059